Atherosclerosis is a chronic inflammatory disease of the arteries, characterised by a build-up of lipids, cellular debris, and other substances, in and on the artery wall. This results in the ...

DEAR DR. ROACH: I recently had a CT scan of my chest and abdomen for pain, and they made a note that I also had coronary atherosclerosis. What is this condition? Can medications help? Can it be ...

In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability ...

THE WEEK'S MOST POPULAR COUNTRY ALBUMS, BASED ON MULTIMETRIC CONSUMPTION, BLENDING TRADITIONAL ALBUM SALES, STREAMING-EQUIVALENT ALBUMS AND TRACK-EQUIVALENT ALBUMS, AS COMPILED BY LUMINATE. Morgan ...

Looking back at animal and clinical studies published since the 1920s, the notion of rapid regression and stabilization of atherosclerosis in humans has evolved from a fanciful goal to one that ...

The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

The win ratio is a method for analyzing a hierarchical composite outcome. It has been most widely used in randomized clinical trials (RCTs) in cardiovascular disease. We performed a review of ...

XRP price has gained 4% over the last 24 hours to $2.43, and its open interest has risen by 25%. Positive spot market activity flips the futures funding rate positive, suggesting a return of ...

Flow allows users to create short video clips and scenes using natural language prompts. It builds upon Google’s earlier experimental tool, VideoFX, and is described as a space where creators ...

The Gold Cup was supposed to be Mauricio Pochettino's last chance to pressure-test his A team. Could his players find a way to control games and start generating a higher quantity and quality of ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.